SCHEMBL24316631

SCHEMBL24316631

CNC(=O)C1CCN(c2cc3c(cc2F)N(c2cc(OC)cc4c2cc(C)c(=O)n4C)CCN3C)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ POLB P06746 2/20 0.35
▸ KMT2A Q03164 4/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.31
▸ HPGD P15428 1/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ BRD1 O95696 1/20 0.31
▸ BRPF1 P55201 1/20 0.31
▸ BRD9 Q9H8M2 1/20 0.31
▸ BRPF3 Q9ULD4 1/20 0.31
▸ TP53 P04637 3/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ TSHR P16473 2/20 0.31
▸ PIK3CD O00329 1/20 0.31
▸ PIK3R1 P27986 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ PIK3CG P48736 1/20 0.31
▸ GPR6 P46095 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24316706 0.88 MAPT (0.36) MAPTTDP1POLBKMT2AMEN1
SCHEMBL24316777 0.85 TP53 (0.39) MAPTTDP1POLBKMT2AMEN1
SCHEMBL24316831 0.85 MAOB (0.38) MAPTKMT2AMEN1NPSR1HPGD
SCHEMBL24316538 0.83 MAP4K4 (0.36) MAPTTDP1POLBKMT2AMEN1
SCHEMBL24316578 0.81 MAPT (0.34) MAPTTDP1POLBKMT2AMEN1
SCHEMBL26548428 0.80 MAPT (0.37) MAPTTDP1POLBKMT2AMEN1
SCHEMBL29471241 0.80 MAPT (0.37) MAPTTDP1POLBKMT2AMEN1
SCHEMBL29471240 0.79 KMT2A (0.35) MAPTTDP1POLBKMT2AMEN1
SCHEMBL26548425 0.79 KMT2A (0.35) MAPTTDP1POLBKMT2AMEN1
SCHEMBL24316689 0.79 CHRM4 (0.36) MAPTTDP1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
WO-2022053967-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS EP300, HDAC1, BRD3 MAPT 1105/4885TDP1 2305/4885POLB 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback